International Journal of Cardiology Publishes Data Demonstrating Superior Outcomes of Stereotaxis Robotic Cardiac Ablation in Pediatric Patients
“We are excited to share data from this large long-term comparative study,” said Dr.
The study’s primary endpoint was long-term freedom from arrhythmia recurrence, with a mean follow-up time of 5.5 years. AV(N)RTs cause abnormally fast heartbeats and are the most common supraventricular tachyarrhythmias (SVT) in children without structural heart disease. Left untreated, frequent episodes may weaken the heart and lead to heart failure. Median age of patients in the study was 14 years at the time of treatment. Patients treated using RMN had 94.4% freedom from arrhythmia recurrence through long-term follow-up, compared to only 85.5% and 59.0% in patients treated with manual RF ablation or cryoablation, respectively (p<0.01).
Although cardiac ablation is a common treatment for AV(N)RT, there is risk of procedural complications, and the impact of procedural radiation on pediatric patients is a concern. In this study, patients who received catheter ablation with RMN experienced zero adverse events, compared with a 2.6% rate of adverse events for manual RF ablation and 2.6% for cryoablation. X-ray exposure was lowest in the RMN procedures, with exposure being 34% and 38% higher with manual RF ablation and cryoablation procedures, respectively.
“Particularly in small hearts, the flexibility and versatility of a magnetic catheter with
The publication can be found at https://www.sciencedirect.com/science/article/pii/S235290672100169X. To access a complete database of more than 400 scientific publications referencing
This press release includes statements that may constitute "forward-looking" statements, usually containing the words "believe”, "estimate”, "project”, "expect" or similar expressions. Forward-looking statements inherently involve risks and uncertainties that could cause actual results to differ materially. Factors that would cause or contribute to such differences include, but are not limited to, the Company's ability to manage expenses at sustainable levels, acceptance of the Company's products in the marketplace, the effect of global economic conditions on the ability and willingness of customers to purchase its technology, competitive factors, changes resulting from healthcare policy, dependence upon third-party vendors, timing of regulatory approvals, the impact of pandemics or other disasters, and other risks discussed in the Company's periodic and other filings with the
Chairman and Chief Executive Officer
Chief Financial Officer
Source: Stereotaxis, Inc.